These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 8970516

  • 21. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
    Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardiès M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
    [Abstract] [Full Text] [Related]

  • 22. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
    Koral KF, Dewaraja Y, Li J, Barrett CL, Regan DD, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL.
    J Nucl Med; 2000 Sep 01; 41(9):1579-86. PubMed ID: 10994741
    [Abstract] [Full Text] [Related]

  • 23. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [Abstract] [Full Text] [Related]

  • 24. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
    Juweid ME, Zhang CH, Blumenthal RD, Hajjar G, Sharkey RM, Goldenberg DM.
    J Nucl Med; 1999 Oct 01; 40(10):1609-16. PubMed ID: 10520699
    [Abstract] [Full Text] [Related]

  • 25. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [Abstract] [Full Text] [Related]

  • 26. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
    DeNardo GL, DeNardo SJ, O'Donnell RT, Kroger LA, Kukis DL, Meares CF, Goldstein DS, Shen S.
    Clin Lymphoma; 2000 Sep 01; 1(2):118-26. PubMed ID: 11707820
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
    O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Carr CE, Mirick GR, DeNardo SJ.
    J Nucl Med; 1999 Dec 01; 40(12):2014-20. PubMed ID: 10616879
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM.
    Clin Cancer Res; 2000 Sep 01; 6(9):3621-8. PubMed ID: 10999754
    [Abstract] [Full Text] [Related]

  • 31. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer.
    Glanzmann C.
    Strahlenther Onkol; 1992 Jun 01; 168(6):337-43. PubMed ID: 1621212
    [Abstract] [Full Text] [Related]

  • 32. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM.
    J Nucl Med; 1997 Mar 01; 38(3):409-18. PubMed ID: 9074529
    [Abstract] [Full Text] [Related]

  • 33. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
    Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, Stabin MG, Sgouros G, American Association of Physicists in Medicine.
    J Nucl Med; 2004 Oct 01; 45(10):1725-33. PubMed ID: 15471841
    [Abstract] [Full Text] [Related]

  • 34. Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin) in breast carcinomas.
    Peterson JA, Blank EW, Ceriani RL.
    Cancer Res; 1997 Mar 15; 57(6):1103-8. PubMed ID: 9067279
    [Abstract] [Full Text] [Related]

  • 35. Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.
    van Zanten-Przybysz I, Molthoff CF, Roos JC, Plaizier MA, Visser GW, Pijpers R, Kenemans P, Verheijen RH.
    J Nucl Med; 2000 Jul 15; 41(7):1168-76. PubMed ID: 10914906
    [Abstract] [Full Text] [Related]

  • 36. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
    Buchmann I, Bunjes D, Kotzerke J, Martin H, Glatting G, Seitz U, Rattat D, Buck A, Döhner H, Reske SN.
    Cancer Biother Radiopharm; 2002 Apr 15; 17(2):151-63. PubMed ID: 12030109
    [Abstract] [Full Text] [Related]

  • 37. WR2721 protection of bone marrow in 131I-labeled antibody therapy.
    Badger CC, Rasey J, Nourigat C, Fisher DR, Hui TE, Wu ZM, Bernstein ID.
    Radiat Res; 1991 Dec 15; 128(3):320-4. PubMed ID: 1660165
    [Abstract] [Full Text] [Related]

  • 38. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
    Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E, Liu CP.
    J Clin Oncol; 1992 Nov 15; 10(11):1696-711. PubMed ID: 1403053
    [Abstract] [Full Text] [Related]

  • 39. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ, Grant EJ, Kasi L, Rosenblum MG, Zhang HZ, Katz RL, Rieger PT, LeBherz D, South M, Greiner JW, Schlom J, Podoloff DA, Murray JL.
    Clin Cancer Res; 1997 Sep 15; 3(9):1547-55. PubMed ID: 9815842
    [Abstract] [Full Text] [Related]

  • 40. Radioimmunotherapy of malignancies.
    Reilly RM.
    Clin Pharm; 1991 May 15; 10(5):359-75. PubMed ID: 2049898
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.